Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290407 · ClinicalTrials.gov registry record · Phase 2
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
A Phase 2 study, sponsored by University of Louisville.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00290407: Clinical Trial Phase 2 study, sponsored by University of Louisville.
NCT00290407 is a Phase 2 study that was terminated before completion, run by University of Louisville. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00290407, a Phase 2 study, was terminated before completion, sponsored by University of Louisville.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan.
Primary Outcome
Study terminated, results data not available
Interventions
- DRUG Rituximab
- DIETARY_SUPPLEMENT Beta-Glucan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Why NCT00290407 stopped before completion
NCT00290407 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00290407 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00290407 about?
NCT00290407 is a clinical study titled "Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)". The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan.
What is the current status of trial NCT00290407?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2006-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00290407?
The interventions under investigation include: Rituximab (DRUG), Beta-Glucan (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00290407?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00290407's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia